How AbbVie, Gilead, Pfizer Are All Gaining From Eli Lilly's RA Rejection Pain
Three pharma stocks that stand to benefit from the announcement by Eli Lilly & Co. and Incyte that the FDA rejected their rheumatoid arthritis pill baricitinib were up Monday.
Gilead Sciences shares rose 56 cents in early trading Monday to $67.06 while Pfizer was up 9 cents to $33.97 and Abbvie up 38 cents to $64.51.
In a statement Friday, Lilly said the FDA has requested additional clinical data to determine appropriate doses of baricitinib. The FDA also asked for more safety data.
Gilead Sciences shares rose 56 cents in early trading Monday to $67.06 while Pfizer was up 9 cents to $33.97 and Abbvie up 38 cents to $64.51.
In a statement Friday, Lilly said the FDA has requested additional clinical data to determine appropriate doses of baricitinib. The FDA also asked for more safety data.